Human natural killer cells are large granular lymphocytes that provide a critical component of the innate immune response. Lacking antigen specificity, they are the least well characterized of lymphocytes, yet the oldest lymphocyte subset in evolution and phylogeny. NK cells make up approximately 15% of all circulating lymphocytes and, through their early production of cytokines and chemokines, are responsible for monocyte/macrophage activation and actively involved in orienting the subsequent antigen specific immune response. Human NK cells can be divided into two subsets based on cell-surface density of CD56, CD56 bright and CD56 dim,each with distinct phenotypic and, as we will present in this project, functional profiles. We will provide preliminary evidence that human NK cell subsets can be distinguished on the basis of their cytokine profiles following activation, and that NK cell expansion and activation are optimized with co-stimulatory signals. This has broad clinical implications, as NK cells produce large amounts of IFN-gamma and promote antibody-dependent cellular cytotoxicity (ADCC). A better understanding of the biology of human NK cell subsets and the factors responsible for their activation will likely identify improved immunotherapeutic strategies to manipulate a more effective anti-tumor activity in clinical cancer trials. We propose to address the following issues relating to NK cell subset activation and cytekine production: 1) to characterize the mechanisms by which human NK cell subsets regulate cytokine production; 2) to investigate CD56 bright and CD56 dim NK receptor expression and recognition of autologous leukemic blasts; and 3) to examine the function of NK cell subsets following Fc activation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA095426-01A1
Application #
6687852
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-09-30
Project End
2007-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Olaverria Salavaggione, Gonzalo N; Duggan, Megan C; Carson, William E (2018) Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. Melanoma Res 28:390-397
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509
Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Dai, Hong-Sheng; Caligiuri, Michael A (2018) Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Front Immunol 9:183
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035

Showing the most recent 10 out of 294 publications